KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke.

Alessandro Marè, Simone Lorenzut, Francesco Janes, Carolina Gentile, Roberto Marinig, Yan Tereshko, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino

Expert Opin Drug Metab Toxicol 20(1-2) 25-36

PMID38275111
PMCID-
DOI10.1080/17425255.2024.2311168
发表日期2024-01-26
摘要

摘要

INTRODUCTION: The drug most frequently used for thrombolysis in cases of acute ischemic stroke (AIS) is alteplase. However, there is moderate-to-high-quality evidence that tenecteplase has similar or higher efficacy and safety. With improved pharmacokinetic properties over alteplase, tenecteplase could be a significant advantage in treating AIS. AREAS COVERED: After conducting an extensive search on Scopus and PubMed, this manuscript reviews and compares the pharmacokinetic properties of alteplase and tenecteplase. Additionally, it provides information on pharmacodynamics, clinical efficacy, safety, tolerability, and drug-drug interactions. EXPERT OPINION: The pharmacokinetic profile of alteplase and tenecteplase is derived from studies in patients with acute myocardial infarction. Thanks to its pharmacokinetic properties, tenecteplase is the drug closest to being the ideal fibrinolytic for AIS. Its longer half-life enables a single-bolus administration, which is particularly useful in emergencies. Tenecteplase has proven to have a good efficacy and safety profile in randomized clinical trials. Although we are awaiting the results of the ongoing phase 3 randomized clinical trials, we believe that tenecteplase has the potential to revolutionize the treatment of AIS through thrombolysis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。